BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 19092296)

  • 1. Hyperparathyroidism 2 gene (HRPT2, CDC73) and parafibromin studies in two patients with primary hyperparathyroidism and uncertain pathological assessment.
    Cetani F; Pardi E; Ambrogini E; Banti C; Viacava P; Borsari S; Bilezikian JP; Pinchera A; Marcocci C
    J Endocrinol Invest; 2008 Oct; 31(10):900-4. PubMed ID: 19092296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surveillance for early detection of aggressive parathyroid disease: carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation.
    Kelly TG; Shattuck TM; Reyes-Mugica M; Stewart AF; Simonds WF; Udelsman R; Arnold A; Carpenter TO
    J Bone Miner Res; 2006 Oct; 21(10):1666-71. PubMed ID: 16995822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism.
    Bricaire L; Odou MF; Cardot-Bauters C; Delemer B; North MO; Salenave S; Vezzosi D; Kuhn JM; Murat A; Caron P; Sadoul JL; Silve C; Chanson P; Barlier A; Clauser E; Porchet N; Groussin L;
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E403-8. PubMed ID: 23293331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort.
    Guarnieri V; Battista C; Muscarella LA; Bisceglia M; de Martino D; Baorda F; Maiello E; D'Agruma L; Chiodini I; Clemente C; Minisola S; Romagnoli E; Corbetta S; Viti R; Eller-Vainicher C; Spada A; Iacobellis M; Malavolta N; Carella M; Canaff L; Hendy GN; Cole DE; Scillitani A
    Cell Oncol (Dordr); 2012 Dec; 35(6):411-22. PubMed ID: 22987117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Young Male with Parafibromin-Deficient Parathyroid Carcinoma Due to a Rare Germline HRPT2/CDC73 Mutation.
    Kapur A; Singh N; Mete O; Hegele RA; Fantus IG
    Endocr Pathol; 2018 Dec; 29(4):374-379. PubMed ID: 30361844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor suppressor gene mutation in a patient with a history of hyperparathyroidism-jaw tumor syndrome and healed generalized osteitis fibrosa cystica: a case report and genetic pathophysiology review.
    Parfitt J; Harris M; Wright JM; Kalamchi S
    J Oral Maxillofac Surg; 2015 Jan; 73(1):194.e1-9. PubMed ID: 25511968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should parafibromin staining replace HRTP2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?
    Cetani F; Ambrogini E; Viacava P; Pardi E; Fanelli G; Naccarato AG; Borsari S; Lemmi M; Berti P; Miccoli P; Pinchera A; Marcocci C
    Eur J Endocrinol; 2007 May; 156(5):547-54. PubMed ID: 17468190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different somatic alterations of the HRPT2 gene in a patient with recurrent sporadic primary hyperparathyroidism carrying an HRPT2 germline mutation.
    Cetani F; Pardi E; Ambrogini E; Viacava P; Borsari S; Lemmi M; Cianferotti L; Miccoli P; Pinchera A; Arnold A; Marcocci C
    Endocr Relat Cancer; 2007 Jun; 14(2):493-9. PubMed ID: 17639062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CDC73/HRPT2 CpG island hypermethylation and mutation of 5'-untranslated sequence are uncommon mechanisms of silencing parafibromin in parathyroid tumors.
    Hahn MA; Howell VM; Gill AJ; Clarkson A; Weaire-Buchanan G; Robinson BG; Delbridge L; Gimm O; Schmitt WD; Teh BT; Marsh DJ
    Endocr Relat Cancer; 2010 Mar; 17(1):273-82. PubMed ID: 20026646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of HRPT2 mutation screening to detect parathyroid carcinoma and atypical parathyroid adenoma of Thai patients.
    Niramitmahapanya S; Sunthornthepvarakul T; Deerochanawong C; Sarinnapakorn V; Athipan P; Harnsomboonvana P; Kongsaengdao S
    J Med Assoc Thai; 2011 Mar; 94 Suppl 2():S17-22. PubMed ID: 21717873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical and morphological characteristics of parathyroid carcinoma].
    Voronkova IA; Mokrysheva NG; Kazantseva IA; Gurevich LE
    Arkh Patol; 2018; 80(4):65-72. PubMed ID: 30059074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parafibromin-deficient (HPT-JT Type, CDC73 Mutated) Parathyroid Tumors Demonstrate Distinctive Morphologic Features.
    Gill AJ; Lim G; Cheung VKY; Andrici J; Perry-Keene JL; Paik J; Sioson L; Clarkson A; Sheen A; Luxford C; Elston MS; Meyer-Rochow GY; Nano MT; Kruijff S; Engelsman AF; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Marsh DJ; Toon CW; Chou A; Clifton-Bligh RJ
    Am J Surg Pathol; 2019 Jan; 43(1):35-46. PubMed ID: 29324469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a novel CDC73 gene mutation in a hyperparathyrodism-jaw tumor patient affected by parathyroid carcinoma in the absence of somatic loss of heterozygosity.
    Ciuffi S; Cianferotti L; Nesi G; Luzi E; Marini F; Giusti F; Zonefrati R; Gronchi G; Perigli G; Brandi ML
    Endocr J; 2019 Apr; 66(4):319-327. PubMed ID: 30799315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of the 2022 WHO Classification of Parathyroid Tumors.
    Erickson LA; Mete O; Juhlin CC; Perren A; Gill AJ
    Endocr Pathol; 2022 Mar; 33(1):64-89. PubMed ID: 35175514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do Patients With Atypical Parathyroid Adenoma Need Close Follow-up?
    Saponaro F; Pardi E; Mazoni L; Borsari S; Torregrossa L; Apicella M; Frustaci G; Materazzi G; Miccoli P; Basolo F; Marcocci C; Cetani F
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4565-e4579. PubMed ID: 34157106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of parafibromin in distant metastatic parathyroid tumors in patients with advanced secondary hyperparathyroidism due to chronic kidney disease.
    Tominaga Y; Tsuzuki T; Matsuoka S; Uno N; Sato T; Shimabukuro S; Goto N; Nagasaka T; Uchida K
    World J Surg; 2008 May; 32(5):815-21. PubMed ID: 18338208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours.
    Juhlin CC; Haglund F; Obara T; Arnold A; Larsson C; Höög A
    Virchows Arch; 2011 Jul; 459(1):47-53. PubMed ID: 21221636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDC73-Related Disorders: Clinical Manifestations and Case Detection in Primary Hyperparathyroidism.
    van der Tuin K; Tops CMJ; Adank MA; Cobben JM; Hamdy NAT; Jongmans MC; Menko FH; van Nesselrooij BPM; Netea-Maier RT; Oosterwijk JC; Valk GD; Wolffenbuttel BHR; Hes FJ; Morreau H
    J Clin Endocrinol Metab; 2017 Dec; 102(12):4534-4540. PubMed ID: 29040582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parafibromin expression, single-gland involvement, and limited parathyroidectomy in familial isolated hyperparathyroidism.
    Iacobone M; Barzon L; Porzionato A; Masi G; Macchi V; Marino F; Viel G; Favia G
    Surgery; 2007 Dec; 142(6):984-91; discussion 984-91. PubMed ID: 18063086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HRPT2 gene analysis and the diagnosis of parathyroid carcinoma.
    Cetani F; Pardi E; Banti C; Borsari S; Ambrogini E; Vignali E; Cianferotti L; Viccica G; Pinchera A; Marcocci C
    Expert Rev Endocrinol Metab; 2008 May; 3(3):377-389. PubMed ID: 30754207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.